Evidence map›Paper›PMID 31097456›Full record

ArticleThe Journal of cell biology2019

Bayonets over bombs: RIPK3 and MLKL restrict

Ting Zhang, Siddharth Balachandran

Open access · bronzeAbstract readComment
In one paragraph

Article in The Journal of cell biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ting ZhangBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA.
Siddharth BalachandranBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA Siddharth.balachandran@fccc.edu.ORCID http://orcid.org/0000-0003-2084-1803
Fox Chase Cancer Center · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell DeathR01AI135025 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH · 2017 to 2025
$6.8M
RIP1/3 Kinases as New Targets in Malignant MesotheliomaR01CA190542 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH, TESTA, JOSEPH R. · 2015 to 2019
$2.1M
Interferon Activated Necroptosis as a New Therapeutic Avenue for Kidney CancerR01CA168621 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH · 2014 to 2018
$1.9M
Targeting RIPK3 in Age-Related Inflammation and InjuryR56AG058642 · NIA · TUFTS UNIVERSITY BOSTON · PI BALACHANDRAN, SIDDHARTH, CUNY, GREGORY D · 2018 to 2018
$649k
NCI NIH HHS P30 CA006927NCI NIH HHS R01 CA168621NCI NIH HHS R01 CA190542NIAID NIH HHS R01 AI135025NIA NIH HHS R56 AG058642
6 · The paper itself

Abstract

RIPK3 induces necroptosis by phosphorylating MLKL, which then induces plasma membrane rupture and necrotic cell death. In this issue, Sai et al. (2019.

Indexed as

BombsListeriaApoptosisHumansNecrosisProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesMLKL protein, humanProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, human

Identifiers

PMID31097456
PMCPMC6548124
OpenAlexW2945850709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.